WXJ-202, a novel Ribociclib derivative, exerts antitumor effects against breast cancer through CDK4/6

• Main Authors: Jing Ji (Author), Wenwen Liu (Author), Yuxin Xu (Author), Zhou Xu (Author), Mingxiao Lv (Author), Jing Feng (Author), Jinyu Lv (Author), Xingbei He (Author), Zhen Zhang (Author), Mengru Xie (Author), Aixin Jing (Author), Xiujun Wang (Author), Jinming Ma (Author), Bin Liu (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Cyclin-dependent kinases 4 and 6 (CDK4/6) are key regulatory proteins in the cell division and proliferative cycle in humans. They are overactive in many malignant tumors, particularly in triple-negative breast cancer (TNBC). Inhibition of CDK4/6 targets can have anti-tumor effects. Here, we designe...